Alembic Pharmaceuticals Ltd. share price target

Revenue decreased by 11.67% to Rs. 769.86 Cr in Q3FY17 when compared to the previous quarter. Also, it fell by 15.9% when compared with Q3FY16.

Alembic Pharma posted lower than expected numbers for 3QFY2017. In sales, the company posted revenues of Rs770cr (Rs872cr expected) v/s Rs921cr in 3QFY2016, dip of 16.4% yoy. The dip in sales was mainly on the back of the International sales, which came in at Rs303cr v/s Rs521cr in 3QFY2016, a dip of 41.8%. The Indian branded sales came i..

ICICI Securities Ltd | Retail Equity Research Revenues declined 16% YoY to | 777 crore (I-direct estimate: | 828 crore) mainly on account of the higher base of gAbilify in the US. Domestic branded formulation sales grew mere 2% YoY to | 294 crore (I-direct estimates: | 326 crore) mainly due to price reduction in Azithral (anti-Infective) and demonetisation EBITDA margins were at 18.7% (I-direct estimate: 19.4%) vs. 42% in Q3FY16 owing to the high base of gAbilify margins...

Alembic Pharmas (ALPM) top line declined 16% YoY, EBITDA margin came in at 18.9% (down 2300bps YoY) and PAT stood at Rs 865mn (down ~68%YoY) in 3QFY17. This is largely attributable to the high base of 3QFY16 which included gAbilify sales. The India branded business growth was also muted at 2% YoY, affected by demonetization and NLEM price cuts. ALPM has a higher exposure to semi-urban and rural segments and hence the demonetization impact was higher.

Alembic Pharmaceuticals posted sales of Rs872cr (vs. Rs1,008cr in 2QFY2016), a dip of 13.5% yoy, mainly on back of base effect. International business declined owing to lower contribution from Abilify. On the operating front, the gross margin is expected to come in at 72.5% (vs. 77.5% in 2QFY2016) and EBIDTA margin at 20.3% (vs. 37.2% in ..

ALPMs top line declined 14% YoY, EBITDA margin came in at 20.4% (-1689bps YoY) and PAT stood at Rs 1.2bn (down 58%YoY) on a high base of 2QFY16 which included substantial gAbilify sales. However, sequential numbers made for better reading with ALPM effecting a revenue growth of 20% on the back of better season for acute products in India business and improved traction in the US base business.

ICICI Securities Ltd | Retail Equity Research Revenues declined 13% YoY to | 879 crore (I-direct estimate: | 817 crore) mainly on account of higher base of gAbilify in Q2FY16. Export sales declined 38% to | 352 crore, higher than I-direct estimate of | 313 crore. Domestic branded formulation sales grew 19% to | 338 crore (I-direct estimates: | 336 crore) on account of 22% growth in the acute portfolio and 16% growth in the speciality portfolio EBITDA margins were at 20.2% (I-direct estimate: 20.0%) vs. 37.3%...

Alembic pharmaceuticals Ltd. (APL) is the Indian pharmaceutical major head quartered in vadodara (Gujarat). The Company is vertically integrated with the ability to develop, manufacture and market pharmaceutical products, pharmaceutical substances and Intermediates. APL is one of the old pharmaceutical companies in India, incorporated in 1907. The company has strong domestic presence in the formulation business. The company has...

For 1QFY2017, Alembic Pharmaceuticals posted sales of Rs727cr V/s Rs583cr in 1QFY2016, ie a yoy growth of 24.8%. Formulations (Rs607.6cr) grew 29.3% yoy, while API (Rs128cr) grew 7.0% yoy. On the operating profit front, the OPM came in at 21.4% V/s 17.4% in 1QFY2016 and V/s 22.7% expected. Expansion in the OPM was mainly on back of gross ..

Incremental revenues from the front-end in the US, and a sequential uptick in gAbilify sales led to 25% YoY revenue growth in 1QFY17. EBITDA at Rs 1.5bn was up 55% YoY and margins improved to 21.3% ( 423bps). Driven by strong operating performance, PAT grew 48% YoY to Rs 1bn.